Overview

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
Phase:
Phase 1
Details
Lead Sponsor:
Akebia Therapeutics
Treatments:
Fluoroquinolones
Glycine
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination